Oryzon Genomics SA(ORYZF)
$2.55-0.02 (-0.58%)
ORYZF
Oryzon Genomics SA financials statements
$2.55
At close:-0.02 (-0.58%)
Oryzon Genomics SA (ORYZF) Ratios
1 Followers
Oryzon Genomics SA Ratios
ORYZF's free cash flow for Q1 2026 was €0.00. For the 2026 fiscal year, ORYZF's free cash flow was increased by €0.00 and operating cash flow was €0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.95 | 0.75 | 0.87 | 1.34 | 3.76 |
| Quick Ratio | 1.94 | 0.74 | 0.87 | 1.34 | 3.75 |
| Cash Ratio | 1.80 | 0.48 | 0.75 | 1.14 | 3.31 |
| Solvency Ratio | -0.09 | -0.16 | -0.13 | -0.13 | -0.19 |
| Operating Cash Flow Ratio | -0.15 | -0.48 | -0.04 | -0.10 | -0.42 |
| Short-Term Operating Cash Flow Coverage | -0.45 | -0.65 | -0.06 | -0.18 | -0.87 |
| Net Current Asset Value | € 3.99M | € -12.93M | € -10.85M | € -5.96M | € 8.48M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.15 | 0.13 | 0.17 | 0.18 |
| Debt-to-Equity Ratio | 0.11 | 0.19 | 0.17 | 0.24 | 0.25 |
| Debt-to-Capital Ratio | 0.10 | 0.16 | 0.14 | 0.19 | 0.20 |
| Long-Term Debt-to-Capital Ratio | 0.06 | 0.08 | 0.04 | 0.09 | 0.16 |
| Financial Leverage Ratio | 1.37 | 1.25 | 1.31 | 1.43 | 1.34 |
| Debt Service Coverage Ratio | -0.57 | -0.25 | -0.14 | -0.26 | -0.95 |
| Interest Coverage Ratio | -10.55 | -3.60 | -2.40 | -4.91 | -15.39 |
| Debt to Market Cap | 0.05 | 0.18 | 0.11 | 0.12 | 0.12 |
| Interest Debt Per Share | 0.17 | 0.27 | 0.26 | 0.33 | 0.34 |
| Net Debt to EBITDA | 2.61 | -2.39 | -0.32 | 0.72 | 1.63 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 95.90% | 0.00% | 0.00% | 92.98% |
| EBIT Margin | 0.00% | -62.26% | 0.00% | 0.00% | -66.07% |
| EBITDA Margin | 0.00% | -60.25% | 0.00% | 0.00% | -64.81% |
| Operating Profit Margin | 0.00% | -60.10% | 0.00% | 0.00% | -66.05% |
| Pretax Profit Margin | 0.00% | -75.71% | 0.00% | 0.00% | -67.64% |
| Net Profit Margin | 0.00% | -49.80% | 0.00% | 0.00% | -44.15% |
| Continuous Operations Profit Margin | 0.00% | -49.81% | 0.00% | 0.00% | -44.15% |
| Net Income Per EBT | 46.54% | 65.78% | 54.93% | 64.53% | 65.28% |
| EBT Per EBIT | 87.22% | 125.96% | 134.18% | 119.44% | 102.41% |
| Return on Assets (ROA) | -1.80% | -3.37% | -3.14% | -4.08% | -4.91% |
| Return on Equity (ROE) | -2.47% | -4.21% | -4.10% | -5.83% | -6.58% |
| Return on Capital Employed (ROCE) | -4.99% | -4.56% | -5.03% | -6.46% | -8.09% |
| Return on Invested Capital (ROIC) | -2.23% | -2.75% | -2.48% | -3.72% | -5.04% |
| Return on Tangible Assets | -7.38% | -31.54% | -3.15% | -15.19% | -13.34% |
| Earnings Yield | -1.13% | -4.07% | -2.74% | -3.04% | -3.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 5.11 | 0.00 | 0.00 | 8.20 |
| Payables Turnover | 0.05 | 0.14 | 0.07 | -3.01 | 0.26 |
| Inventory Turnover | 35.89 | 101.47 | 40.42 | -1554.81 | 7.19 |
| Fixed Asset Turnover | 0.00 | 20.70 | 0.00 | 0.00 | 15.55 |
| Asset Turnover | 0.00 | 0.07 | 0.00 | 0.00 | 0.11 |
| Working Capital Turnover Ratio | 0.00 | -2.87 | 0.00 | 0.00 | 0.36 |
| Cash Conversion Cycle | -7494.15 | -2493.20 | -5105.14 | 121.12 | -1328.45 |
| Days of Sales Outstanding | 0.00 | 71.42 | 0.00 | 0.00 | 44.49 |
| Days of Inventory Outstanding | 10.17 | 3.60 | 9.03 | -0.23 | 50.79 |
| Days of Payables Outstanding | 7504.32 | 2568.22 | 5114.17 | -121.35 | 1423.73 |
| Operating Cycle | 10.17 | 75.02 | 9.03 | -0.23 | 95.28 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.03 | -0.09 | -0.01 | -0.03 | -0.07 |
| Free Cash Flow Per Share | -0.03 | -0.21 | -0.25 | -0.29 | -0.29 |
| Dividend Paid and CapEx Coverage Ratio | -39.67 | -0.74 | -0.04 | -0.13 | -0.31 |
| Capital Expenditure Coverage Ratio | -39.67 | -0.74 | -0.04 | -0.13 | -0.31 |
| Operating Cash Flow Coverage Ratio | -0.20 | -0.35 | -0.04 | -0.11 | -0.21 |
| Operating Cash Flow to Sales Ratio | 0.00 | -0.77 | 0.00 | 0.00 | -0.34 |
| Free Cash Flow Yield | -1.04% | -14.87% | -12.32% | -11.60% | -10.80% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -88.86 | -24.60 | -36.49 | -32.85 | -30.39 |
| Price-to-Sales (P/S) Ratio | 0.00 | 12.25 | 0.00 | 0.00 | 13.42 |
| Price-to-Book (P/B) Ratio | 2.19 | 1.04 | 1.50 | 1.92 | 2.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -95.74 | -6.73 | -8.12 | -8.62 | -9.26 |
| Price-to-Operating Cash Flow Ratio | -98.16 | -15.84 | -212.83 | -75.23 | -39.28 |
| Price-to-Earnings Growth (PEG) Ratio | 2.31 | -7.53 | 1.35 | 2.19 | -0.80 |
| Enterprise Value Multiple | -34.19 | -22.71 | -27.92 | -25.25 | -19.08 |
| Enterprise Value | 214.86M | 100.71M | 123.80M | 135.11M | 131.25M |
| EV to EBITDA | -34.19 | -22.71 | -27.92 | -25.25 | -19.08 |
| EV to Sales | 0.00 | 13.69 | 0.00 | 0.00 | 12.36 |
| EV to Free Cash Flow | -88.95 | -7.52 | -8.21 | -8.38 | -8.53 |
| EV to Operating Cash Flow | -91.19 | -17.70 | -215.31 | -73.13 | -36.19 |
| Tangible Book Value Per Share | 0.12 | -0.16 | 1.34 | -0.06 | 0.21 |
| Shareholders’ Equity Per Share | 1.42 | 1.35 | 1.34 | 1.29 | 1.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.53 | 0.34 | 0.45 | 0.35 | 0.35 |
| Revenue Per Share | 0.00 | 0.11 | 0.00 | 0.00 | 0.20 |
| Net Income Per Share | -0.04 | -0.06 | -0.06 | -0.08 | -0.09 |
| Tax Burden | 0.47 | 0.66 | 0.55 | 0.65 | 0.65 |
| Interest Burden | 0.87 | 1.22 | 1.34 | 1.19 | 1.02 |
| Research & Development to Revenue | 0.00 | 1.15 | 0.00 | 0.00 | 0.69 |
| SG&A to Revenue | 0.00 | 0.47 | 0.00 | 0.00 | 1.23 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.90 | 1.55 | 0.17 | 0.75 | 0.77 |
Currency in EUR

